Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis
نویسندگان
چکیده
منابع مشابه
Clinical use of nintedanib in patients with idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterised by progressive loss of lung function, dyspnoea and cough. IPF has a variable clinical course but a poor prognosis. Nintedanib, a tyrosine kinase inhibitor, is one of two drugs approved for the treatment of IPF. In clinical trials, nintedanib slowed disease progression by reducing the rate of decline in forced vital capacit...
متن کاملClinical use of nintedanib in patients with idiopathic pulmonary fibrosis
Hajari Case A, Johnson P. BMJ Open Resp Res 2017;4:e000192. doi:10.1136/bmjresp-2017-000192 AbstrAct Idiopathic pulmonary fibrosis (IPF) is a rare lung disease characterised by progressive loss of lung function, dyspnoea and cough. IPF has a variable clinical course but a poor prognosis. Nintedanib, a tyrosine kinase inhibitor, is one of two drugs approved for the treatment of IPF. In clinical ...
متن کاملChange in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
BACKGROUND Idiopathic pulmonary fibrosis (IPF) is a rare and serious disease characterized by progressive lung-function loss. Limited evidence has been published on the impact of lung-function loss on subsequent patient outcomes. This study examined change in forced vital capacity (FVC) across IPF patients in the 6 months after diagnosis and its association with clinical and healthcare resource...
متن کاملRelative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.
BACKGROUND Decline in forced vital capacity (FVC) over time reliably predicts mortality in patients with idiopathic pulmonary fibrosis. The use of this measure in clinical practice is recommended by current evidence-based guidelines. It is unknown if the method of calculating decline in FVC (relative vs. absolute change) impacts its frequency or its ability to predict mortality. METHODS Patie...
متن کاملTreatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis
There is currently no effective treatment for acute exacerbation of idiopathic pulmonary fibrosis (IPF). We herein report the case of a patient with acute exacerbation of IPF which was treated with nintedanib, an intracellular inhibitor of tyrosine kinases, and showed improvement of the condition. An 84-year-old man with IPF was admitted to our hospital because of dry cough and worsening of dys...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Journal
سال: 2018
ISSN: 0903-1936,1399-3003
DOI: 10.1183/13993003.02593-2017